Phathom Pharmaceuticals (PHAT) Competitors $8.33 -0.21 (-2.46%) Closing price 04:00 PM EasternExtended Trading$8.42 +0.09 (+1.08%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. IBRX, GMTX, ARWR, APLS, TWST, NAMS, APGE, RXRX, DNLI, and VCELShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Twist Bioscience (TWST), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Its Competitors ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals Twist Bioscience NewAmsterdam Pharma Apogee Therapeutics Recursion Pharmaceuticals Denali Therapeutics Vericel ImmunityBio (NASDAQ:IBRX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Does the media favor IBRX or PHAT? In the previous week, ImmunityBio and ImmunityBio both had 3 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 0.97 beat ImmunityBio's score of 0.23 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phathom Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, IBRX or PHAT? ImmunityBio has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Which has preferable earnings and valuation, IBRX or PHAT? Phathom Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.74M164.67-$413.56M-$0.58-4.74Phathom Pharmaceuticals$55.25M10.53-$334.33M-$5.24-1.59 Is IBRX or PHAT more profitable? Phathom Pharmaceuticals has a net margin of -422.42% compared to ImmunityBio's net margin of -1,310.30%. Company Net Margins Return on Equity Return on Assets ImmunityBio-1,310.30% N/A -121.88% Phathom Pharmaceuticals -422.42%N/A -90.11% Do analysts prefer IBRX or PHAT? ImmunityBio presently has a consensus price target of $12.25, suggesting a potential upside of 345.45%. Phathom Pharmaceuticals has a consensus price target of $17.50, suggesting a potential upside of 110.08%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImmunityBio is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of IBRX or PHAT? 8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 76.8% of ImmunityBio shares are held by company insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryPhathom Pharmaceuticals beats ImmunityBio on 7 of the 12 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$596.21M$2.92B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.4928.6119.73Price / Sales10.53266.14412.31173.11Price / CashN/A43.1536.0257.96Price / Book-2.257.768.235.67Net Income-$334.33M-$55.11M$3.23B$257.79M7 Day Performance-11.10%0.95%-0.01%0.52%1 Month Performance-21.71%8.44%5.61%8.84%1 Year Performance-31.83%-2.38%26.52%14.18% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals4.1927 of 5 stars$8.33-2.5%$17.50+110.1%-32.6%$596.21M$55.25M0.00110IBRXImmunityBio2.1436 of 5 stars$2.72flat$12.25+350.4%-56.9%$2.40B$14.74M0.00590Gap UpGMTXGemini TherapeuticsN/A$54.75+3.0%N/A+22.4%$2.37BN/A-54.7530News CoverageARWRArrowhead Pharmaceuticals3.5665 of 5 stars$16.84+0.3%$43.71+159.6%-38.9%$2.32B$3.55M0.00400News CoverageAPLSApellis Pharmaceuticals4.2364 of 5 stars$17.42-4.6%$39.79+128.4%-51.6%$2.29B$781.37M0.00770News CoverageAnalyst ForecastInsider TradeAnalyst RevisionTWSTTwist Bioscience4.1891 of 5 stars$35.59-6.8%$50.40+41.6%-35.2%$2.29B$312.97M-10.95990Positive NewsNAMSNewAmsterdam Pharma2.7406 of 5 stars$19.46-2.0%$42.89+120.4%+7.3%$2.23B$45.56M0.004APGEApogee Therapeutics3.0648 of 5 stars$39.24-17.3%$99.00+152.3%-24.8%$2.19BN/A0.0091High Trading VolumeRXRXRecursion Pharmaceuticals1.8048 of 5 stars$4.93-6.5%$7.00+42.0%-36.3%$2.14B$58.84M0.00400DNLIDenali Therapeutics4.6833 of 5 stars$14.25-3.0%$33.71+136.6%-39.3%$2.13B$330.53M0.00430Positive NewsVCELVericel3.7025 of 5 stars$39.41-5.6%$61.14+55.1%-25.6%$2.10B$237.22M1,391.33300News Coverage Related Companies and Tools Related Companies ImmunityBio Alternatives Gemini Therapeutics Alternatives Arrowhead Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Twist Bioscience Alternatives NewAmsterdam Pharma Alternatives Apogee Therapeutics Alternatives Recursion Pharmaceuticals Alternatives Denali Therapeutics Alternatives Vericel Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAT Stock Alerts